Roscovitine (also known as CYC202 or Seliciclib), a pan-CDK inhibitor [33] currently in phase II clinical trials for breast and lung carcinomas [31], inhibited the activity of VRK2 (Fig. 3B) by fifty percent at approximately 25 μM, which is higher than the one reported for inhibition of CDK1/cyclinB, and CDK2/cyclinA (0.7 μM) [34]. This evidence concerns the gene CDK2 and lung carcinoma.